Abbott completes $105-per-share cash acquisition of Exact Sciences
Abbott Laboratories completed its acquisition of Exact Sciences on March 23, 2026, under a merger agreement dated November 19, 2025. Exact Sciences shareholders received $105.00 in cash per share, and Exact Sciences is now a wholly owned Abbott subsidiary, so shareholders of both companies should watch how the combined business is integrated.
Key points
- Each Exact Sciences common share was converted into the right to receive $105.00 in cash, without interest, less applicable withholding taxes.
- March 20, 2026 was the last day Exact Sciences shares traded on the Nasdaq Stock Market.
- Exact Sciences survives the merger as a direct, wholly owned subsidiary of Abbott.
- Abbott says the deal adds Cologuard, Oncotype DX, Oncodetect and Cancerguard to its diagnostics portfolio.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 23, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.